natgillin/translations-raw huggingface dataset:
• Do not use this medicine after the expiry date which is stated on the carton and the vial label after EXP. 
• Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in nalepki viale poleg oznak Uporabno do/EXP.
Tecentriq is available in a pack containing 1 glass vial. 
Zdravilo Tecentriq je na voljo v pakiranjih, ki vsebujejo 1 stekleno vialo.
The following categories of frequency have been used: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to 
Uporabljene so naslednje kategorije pogostnosti: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1000 do < 1/100), redki (≥ 1/10.000 do < 1/1000), zelo redki (< 1/10.000).
The use of in-line filter membranes is optional. 
Uporaba linijskega membranskega filtra ni obvezna.
Primary efficacy endpoints n=185 
Primarni opazovani dogodki učinkovitosti n = 185
A decision must be made whether to discontinue breast-feeding or to discontinue Tecentriq therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. 
Odločiti se je treba ali za prenehanje dojenja ali za prenehanje uporabe zdravila Tecentriq, upoštevaje koristi dojenja za otroka in koristi zdravljenja za žensko.
However, monoclonal antibodies are not expected to alter DNA or chromosomes. 
Za monoklonska protitelesa ni pričakovano, da bi spremenila DNA ali kromosome.
• decreased number of lymphocyte (a type of white blood cells), which is associated with an increased risk of infection 
• zmanjšano število limfocitov (vrste belih krvnih celic), ki je povezano s povečanim tveganjem okužbe
Do not co-administer other medicinal products through the same infusion line. 
Drugih zdravil ne dajate sočasno z isto infuzijsko linijo.
Treatment with atezolizumab until loss of clinical benefit was permitted as defined by the following criteria: 
Zdravljenje z atezolizumabom do izgube klinične koristi je bilo dovoljeno, kot je opredeljeno v naslednjih merilih:
Tell your doctor straight away if you notice any of the symptoms below: 
Zdravnika morate takoj obvestiti, če opazite katerega od naslednjih simptomov:
Patients excluded from clinical trials 
Bolniki, ki niso bili vključeni v klinična preskušanja
• myasthenia gravis, an illness that can cause muscle weakness 
• miastenija gravis, bolezen, ki lahko povzroči šibkost mišic
*** Responses were ongoing in 63% of responders in the atezolizumab arm and in 21% of responders in the chemotherapy arm. 
*** Odgovori so potekali pri 63 % odzivnih bolnikov v skupini z atezolizumabom in pri 21 % odzivnih bolnikov v skupini s kemoterapijo.
Isolated hypothyroidism may be managed with replacement therapy and without corticosteroids. 
Izolirani hipotiroidizem je mogoče urejati z nadomestnim zdravljenjem in brez kortikosteroidov.
• The card should also prompt to enter contact details of the physician and include a warning message for healthcare professionals treating the patient at any time, including in conditions of emergency, that the patient is using Tecentriq. 
• Kartica mora vključevati tudi prostor za navedbo kontaktnih podatkov zdravnika in vsebovati opozorilo za zdravstvene delavce, ki kadarkoli zdravijo bolnika, tudi v nujnih stanjih, da bolnik uporablja zdravilo Tecentriq.
• Warning message for patients on the importance of consulting their doctor immediately in case they develop any of the listed signs and symptoms and on the important not attempting to treat themselves. 
• Opozorilo za bolnike glede pomena takojšnjega posvetovanja z zdravnikom, če imajo kateregakoli od navedenih znakov in simptomov, ter o pomembnosti dejstva, da se ne poskušajo zdraviti sami.
• Absence of tumour progression at critical anatomical sites (e.g., leptomeningeal disease) that cannot be readily managed and stabilised by protocol-allowed medical interventions prior to repeat dosing 
• odsotnost napredovanja tumorja na kritičnih anatomskih mestih (npr. leptomeningealna bolezen), ki jih pred ponovno uporabo zdravila ni mogoče enostavno obvladati in stabilizirati z zdravljenjem, dovoljenim po protokolu;
*The primary analysis population consists of the first 850 randomised patients 
*Populacijo za primarno analizo sestavlja prvih 850 randomiziranih bolnikov.
Atezolizumab should not be used during pregnancy unless the clinical condition of the woman requires treatment with atezolizumab. 
Atezolizumaba se med nosečnostjo ne sme uporabljati, razen če bolničino klinično stanje zahteva zdravljenje z atezolizumabom.
Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2 
Stanje zmogljivosti po ECOG (Eastern Cooperative Oncology Group) ≥ 2
If you notice any of the symptoms above, tell your doctor straight away. 
Če opazite katerega od zgoraj naštetih simptomov, morate takoj obvestiti zdravnika.
The primary analysis was performed when all patients had at least 24 weeks of follow-up. 
Primarna analiza je bila izvedena, ko so vse bolnike spremljali vsaj 24 tednov.
It belongs to a group of medicines called monoclonal antibodies. 
Spada v skupino zdravil, imenovanih monoklonska protitelesa.
• have human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome 
• imate okužbo z virusom humane imunske pomanjkljivosti (HIV) ali sindrom pridobljene imunske pomanjkljivosti (AIDS),
No dose adjustments are recommended. 
Drugih sprememb niso priporočili.
(10.0, NE) 
(10,0; NO)
Atezolizumab is a monoclonal antibody and is expected to be present in the first milk and at low levels afterwards. 
Atezolizumab je monoklonsko protitelo in pričakovano je, da je prisoten v prvem mleku ter v majhni koncentraciji pozneje.
The key results from this analysis as well as from the updated PFS analysis in the ITT population are summarised in Tables 6 and 7. 
Ključni rezultati te analize kot tudi posodobljene analize PFS v populaciji ITT so povzeti v preglednicah 6 in 7.
The recommended dose is either: 
Priporočeni odmerek je:
The MAH shall ensure that in each Member State where Tecentriq is marketed, all healthcare professionals and patients/carers who are expected to prescribe and use Tecentriq have access to/are provided with the following educational package: 
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da bodo v vseh državah članicah, kjer se zdravilo Tecentriq trži, vsi zdravstveni delavci in bolniki/skrbniki, za katere se pričakuje, da bodo predpisovali ali uporabljali zdravilo Tecentriq, imeli dostop ali prejeli naslednji paket izobraževanih gradiv:
The recommended dose of Tecentriq is: 
Priporočeni odmerek zdravila Tecentriq je:
Seven (0.2%) patients required the use of corticosteroids. 
Pri 7 (0,2 %) bolnikih je bilo treba uporabiti kortikosteroide.
** Based on Kaplan-Meier estimate 
** Na osnovi Kaplan-Meierjeve ocene.
Due to increased haematologic toxicities observed in Asian patients in IMpower150, it is recommended that the starting dose of paclitaxel should be 175 mg/m2 every three weeks. 
Zaradi povečane hematološke toksičnosti, ki so jo opazili pri azijskih bolnikih v študiji IMpower150, je priporočljivo, da je začetni odmerek paklitaksela 175 mg/m na tri tedne.
Further details on serious adverse reactions are provided in Section 4.4 Warnings & Precautions. 
Nadaljnje podrobnosti o resnih neželenih učinkih so navedene v poglavju 4.4 Posebna opozorila in previdnostni ukrepi.
Patients experiencing fatigue should be advised not to drive and use machines until symptoms abate (see section 4.8). 
Bolnikom, ki se jim pojavi utrujenost, je treba naročiti, naj ne vozijo in ne upravljajo strojev, dokler simptomi ne izzvenijo (glejte poglavje 4.8).
Seventy-five percent of patients received only one prior platinum-based therapeutic regimen. 
75 % bolnikov je prejelo le eno predhodno terapevtsko shemo na osnovi platine.
No data are available to allow conclusions to be drawn on possible effects of neutralising antibodies. 
Podatkov, ki bi omogočili sklepanje na morebitne učinke nevtralizirajočih protiteles, ni na voljo.
• Store in a refrigerator (2 °C - 8 °C). 
• Shranjujte v hladilniku (2 °C do 8 °C).
The time to onset was 1.2 months. 
Čas do pojava je bil 1,2 meseca.
Patients who met established criteria and who agreed to be treated beyond disease progression had tumour assessments conducted every 6 weeks until treatment discontinuation. 
Bolnikom, ki so izpolnjevali postavljena merila in so soglašali z zdravljenjem po napredovanju bolezni, so oceno tumorja opravili vsakih 6 tednov do prenehanja zdravljenja.
The primary analysis of Cohort 2 was performed when all patients had at least 24 weeks of follow-up. 
Primarna analiza 2. kohorte je bila izvedena, ko so vse bolnike spremljali vsaj 24 tednov.
• Absence of symptoms and signs (including worsening of laboratory values [e.g., new or worsening hypercalcaemia]) indicating unequivocal progression of disease 
• odsotnost simptomov in znakov (vključno s poslabšanjem laboratorijskih vrednosti [npr. novonastalo hiperkalciemijo ali poslabšanjem hiperkalciemije]), ki nedvomno kažejo napredovanje bolezni;
These results indicate a potential risk, based on its mechanism of action, that administration of atezolizumab during pregnancy could cause foetal harm, including increased rates of abortion or stillbirth. 
Ti rezultati kažejo možno tveganje, da bi uporaba atezolizumaba med nosečnostjo zaradi njegovega mehanizma delovanja lahko povzročila okvaro ploda, vključno z večjimi deleži splavov ali mrtvorojenosti.
This is because the effect of Tecentriq in pregnant women is not known - it is possible that it could harm your unborn baby. 
Vpliv zdravila Tecentriq pri nosečnicah namreč ni znan in zdravilo bi morda lahko škodovalo vašemu nerojenemu otroku.
• Periodic safety update reports The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 
• Redno posodobljena poročila o varnosti zdravila (PSUR) Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
Among 107 Arm B patients who had a response status of stable disease, partial response, or complete response after induction therapy, 40 received pemetrexed switch maintenance therapy. 
Od 107 bolnikov v skupini B, ki so po uvodnem zdravljenju dosegli odziv stabilne bolezni, delnega odgovora ali popolnega odgovora, jih je 40 nadaljevalo vzdrževalno zdravljenje zamenjano s pemetreksedom.
For suspected immune-related adverse reactions, thorough evaluation to confirm aetiology or exclude other causes should be performed. 
Pri sumu na imunsko pogojene neželene učinke je treba opraviti temeljito oceno za potrditev etiologije oziroma izključitev drugih vzrokov.
Based on limited data from clinical studies in patients whose immune-related adverse reactions could not be controlled with systemic corticosteroid use, administration of other systemic immunosuppressants may be considered. 
Na podlagi majhnega števila podatkov iz kliničnih študij pri bolnikih, katerih imunsko pogojenih neželenih učinkov ni mogoče nadzorovati s sistemskim zdravljenjem s kortikosteroidi, se lahko razmisli o uvedbi drugih sistemskih imunosupresivov.
This protein suppresses the body's immune (defense) system, thereby protecting cancer cells from being attacked by the immune cells. 
Ta beljakovina zavira imunski (obrambni) sistem telesa, s čimer ščiti rakave celice pred napadom imunskih celic.
• numbness or paralysis, which may be signs of Guillain-Barré syndrome 
• omrtvičenost ali paraliza, ki sta lahko znaka t. i. Guillain-Barréjevega sindroma
• If you do not have an infusion reaction during the first infusion, the next infusions will be given to you over a period of 30 minutes. 
• Če med prvo infuzijo ne boste imeli reakcije na infundiranje, boste naslednje infuzije prejeli v
How long treatment lasts 
Kako dolgo traja zdravljenje
There are no data from the use of atezolizumab in pregnant women. 
Podatkov o uporabi atezolizumaba pri nosečnicah ni.
OS was not mature with an event patient ratio of approximately 40%. 
Celokupno preživetje ni bilo dozorelo; razmerje bolnikov z dogodki je bilo približno 40 %.
Patients received treatment until radiographic disease progression per RECIST v1.1, or unacceptable toxicity. 
Bolniki so zdravljenje prejemali do radiografskega napredovanja po merilih RECIST v1.1 ali do nesprejemljivih toksičnih učinkov.
As a consequence, no formal tests of statistical significance could be performed for OS in the IC1/2/3 or all comer populations, and results of those analyses would be considered exploratory. 
Posledično niso mogli izvesti formalnih testov statistične značilnosti za celokupno preživetje v populacijah IC1/2/3 in neselekcioniranih bolnikov, te rezultate smatramo kot raziskovalne.
Your doctor will keep giving you Tecentriq until you no longer benefit from it. 
Zdravnik vam bo zdravilo Tecentriq dajal, vse dokler vam bo koristilo.
In the IMpassion130 study, of the 614 patients tested, 89 (15%) carried pathogenic BRCA1/2 mutations. 
V študiji IMpassion130 je imelo od 614 testiranih bolnikov 89 (15 %) patogene mutacije BRCA1/2.
Reminder to educate patients/caregivers about the symptoms of immune-related adverse reactions and of the need to report them immediately to the physician. 
Opomnik za izobraževanje bolnikov/skrbnikov o simptomih imunsko pogojenih neželenih učinkov in o nujnosti njihovega takojšnjega poročanja zdravniku.
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and bilirubin should be monitored prior to initiation of treatment, periodically during treatment with atezolizumab and as indicated based on clinical evaluation. 
Vrednosti aspartat-aminotransferaze (AST), alanin-aminotransferaze (ALT) in bilirubina je treba spremljati pred začetkom zdravljenja z atezolizumabom, redno med zdravljenjem in kot je potrebno glede na klinično oceno.
* An analysis of OS in the all comer population was performed based on the stratified log-rank test and the result is provided for descriptive purposes only (p = 0.0378); according to the pre-specified analysis hierarchy, the p-value for the OS analysis in the all comer population cannot be considered statistically significant. 
* Analizo celokupnega preživetja v populaciji neselekcioniranih bolnikov so izvedli na osnovi stratificiranega testa log-rang; rezultat je predviden le za opisne namene (p = 0,0378); v skladu s predhodno določeno hierarhijo analiz, p-vrednosti za analizo celokupnega preživetja v populaciji neselekcioniranih bolnikov ne moremo smatrati za statistično značilno.
• pain in the muscles and bones 
• bolečine v mišicah in kosteh
Unstratified HR for other exploratory subgroups. 
Nestratificirano razmerje ogroženosti za druge raziskovalne podskupine.
Patient demographics and baseline tumour disease in patients with PD-L1 expression ≥1% were generally representative of the broader study population. 
Demografija in izhodiščna tumorska bolezen pri bolnikih z izražanjem PD-L1 ≥ 1 % sta bili na splošno reprezentativni za širšo raziskovano populacijo.
Tecentriq is used to treat adults with: 
Tecentriq uporabljamo za zdravljenje odraslih z:
Based on the stratified log-rank test. 
na osnovi stratificiranega testa log-rang
By attaching to the protein, Tecentriq helps your immune system to fight your cancer. 
Z vezavo na to beljakovino zdravilo Tecentriq vašemu imunskemu sistemu pomaga premagovati raka.
A population pharmacokinetic analysis indicates that the clearance of atezolizumab is 0.200 L/day and the typical terminal elimination half-life is 27 days. 
Populacijska farmakokinetična analiza kaže, da je očistek atezolizumaba 0,200 l/dan in da je tipični končni razpolovni čas izločanja 27 dni.
Do not stop treatment with Tecentriq unless you have discussed this with your doctor. 
Ne prenehajte zdravljenja z zdravilom Tecentriq, ne da bi se o tem posvetovali z zdravnikom.
• allergic reaction (infusion-related reaction, hypersensitivity or anaphylaxis) 
• alergijska reakcija (z infundiranjem povezana reakcija, preobčutljivost ali anafilaksija)
Treatment beyond disease progression was permitted at the discretion of the physician. 
Zdravljenje po napredovanju bolezni je bilo dovoljeno po presoji zdravnika.
Patients, including those with EGFR mutations or ALK rearrangements, were enrolled and were randomised in a 2:1 ratio to receive one of the treatment regimens described in Table 8. 
Bolnike, vključno s tistimi, ki so imeli mutacije EGFR ali preureditve ALK, so vključili in jih v razmerju 2:1 randomizirali na prejemanje ene od shem zdravljenja, opisanih v preglednici 8.
• Information that atezolizumab can cause serious side effects during or after treatment, that need to be treated right away 
• Informacije, da lahko atezolizumab med zdravljenjem ali po njem povzroči resne neželene učinke, ki jih je treba zdraviti takoj.
Women of childbearing potential have to use effective contraception during and for 5 months after treatment with atezolizumab. 
Ženske v rodni dobi morajo med zdravljenjem in še 5 mesecev po zdravljenju z atezolizumabom uporabljati učinkovito kontracepcijsko zaščito.
Body weight, gender, positive ADA status, albumin levels and tumour burden have a statistically significant, but not clinically relevant effect on atezolizumab pharmacokinetics. 
Telesna masa, spol, pozitivno stanje ADA, koncentracija albumina in tumorsko breme imajo statistično značilen učinek na farmakokinetiko atezolizumaba, ki pa ni klinično pomemben.
For instructions on dilution and handling of the medicinal product before administration, see section 6.6. 
Za navodila o razredčenju in ravnanju z zdravilom pred dajanjem glejte poglavje 6.6.
At the time of the updated OS analysis, an exploratory PFS analysis was performed as presented in Table 6. 
V času posodobljene analize OS je bila izvedena eksploratorna analiza PFS, ki je predstavljena v preglednici 6.
Tecentriq has minor influence on your ability to drive and use machines. 
Zdravilo Tecentriq ima blag vpliv na sposobnost vožnje in upravljanja strojev.
The use of systemic corticosteroids or immunosuppressants before starting atezolizumab should be avoided because of their potential interference with the pharmacodynamic activity and efficacy of atezolizumab. 
Uporabi sistemskih kortikosteroidov ali imunosupresivov se je pred uvedbo atezolizumaba treba izogibati, ker lahko vplivajo na farmakodinamično aktivnost in učinkovitost atezolizumaba.
Patients with EGFR mutations or ALK rearrangements should have been previously treated with tyrosine kinase inhibitors. 
Bolniki z mutacijami EGFR ali preureditvami ALK so morali biti predhodno zdravljeni z zaviralci tirozin kinaze.
Atezolizumab must be permanently discontinued for any Grade 3 immune-related adverse reaction that recurs and for any Grade 4 immune-related adverse reactions, except for endocrinopathies that are controlled with replacement hormones (see sections 4.2 and 4.8). 
Atezolizumab je treba trajno prenehati uporabljati pri vseh imunsko pogojenih neželenih učinkih 3. stopnje, ki se ponovijo, in pri vseh imunsko pogojenih neželenih učinkih 4. stopnje, z izjemo endokrinopatij, ki jih je mogoče nadzorovati z nadomestnimi hormoni (glejte poglavji 4.2 in 4.8).
Patients should be monitored for changes in renal function. 
Bolnike je treba nadzorovati glede sprememb v delovanju ledvic.
• feeling very tired (fatigue) 
• občutek hude utrujenosti (izčrpanost)
The majority of patients had a baseline ECOG performance status of 1 (59%) and PDL1 expression <1% (approximately 52%). 
Večina bolnikov je imela izhodiščno stanje zmogljivosti po ECOG 1 (59 %) in izražanje PD-L1 < 1 % (približno 52 %).
• low number of red blood cells, which can cause tiredness and shortness of breath 
• majhno število rdečih krvnih celic, ki lahko povzroči utrujenost in težko dihanje
The time to deterioration in other lung cancer symptoms (i.e. cough, dyspnoea, and arm/shoulder pain) as measured by the EORTC QLQ-LC13 was similar between atezolizumab and docetaxel. 
Čas do poslabšanja drugih simptomov raka pljuč (tj. kašlja, dispneje in bolečin v roki/rami), merjenih z EORTC QLQ-LC13, je bil z atezolizumabom in docetakselom podoben.
What you need to know before you are given Tecentriq 
Kaj morate vedeti, preden boste dobili zdravilo Tecentriq
• prepared in a laminar flow hood or biological safety cabinet using standard precautions for the safe handling of intravenous agents. 
• Priprava mora potekati v komori z laminarnim pretokom zraka ali v varnostni komori za pripravo bioloških zdravil; upoštevati je treba standardne previdnostne ukrepe za varno ravnanje z intravenskimi zdravili.
• 840 milligrams (mg) every two weeks, or 
• 840 miligramov (mg) na dva tedna ali
Tecentriq must be initiated and supervised by physicians experienced in the treatment of cancer. 
Zdravilo Tecentriq morajo uvesti in nadzorovati zdravniki z izkušnjami pri zdravljenju raka.
Your first infusion will be given over 60 minutes. 
Prva infuzija, ki jo boste dobili, bo trajala 60 minut.
14.1 (9.2, NE) 15.9 (10.4, NE) 
12,3 (6,0; NO) 14,1 (9,2; NO) 15,9 (10,4; NO)
Median duration of PFS (months) 
Mediano trajanje PFS (meseci)
Based on exploratory analysis and acknowledging the small sample size, the presence of BRCA1/2 mutation does not seem to impact the PFS clinical benefit of atezolizumab and nab-paclitaxel. 
Na podlagi eksploratorne analize in upoštevanja majhne velikosti vzorca se zdi, da prisotnost mutacije BRCA1/2 nima vpliva na klinično korist atezolizumaba in nabpaklitaksela v smislu PFS.
Most patients were women (99.6%), 67.5% were white and 17.8% Asian. 
Večina vključenih je bila žensk (99,6 %), 67,5 % je bilo belk in 17,8 % Azijk.
The initial dose of Tecentriq must be administered over 60 minutes. 
Začetni odmerek zdravila Tecentriq je treba dati v 60 minutah.
The effect of age on the pharmacokinetics of atezolizumab was assessed in a population pharmacokinetic analysis. 
Vpliv starosti na farmakokinetiko atezolizumaba so ocenili v populacijski farmakokinetični analizi.
The demographics and baseline disease characteristics of the study population defined as ITT-WT (n=679) were well balanced between the treatment arms. 
Demografske značilnosti in izhodiščne značilnosti bolezni v študijski populaciji, opredeljeni kot populacija ITT-divji tip (n = 679), so bile med terapevtskima skupinama dobro uravnotežene.
Per final analysis for PFS, ORR, DOR and first interim analysis for OS at clinical cut off 17th April 2018 
3. po končni analizi PFS, ORR, DOR in prvi vmesni analizi OS na klinični presečni datum 17. april 2018;
PFS, ORR and DOR results of IMpassion130 for patients with PD-L1 expression ≥ 1% at the time of the final analysis for PFS with a median survival follow up of 13 months are summarized in Table 6 with Kaplan-Meier curves for PFS in Figure 4. 
Rezultati PFS, ORR in DOR v preskušanju IMpassion130 pri bolnikih z izražanjem PD-L1 ≥ 1 % v času končne analize PFS z medianim spremljanjem preživetja 13 mesecev so povzeti v preglednici 6 in s Kaplan-Meierjevima krivuljama za PFS na sliki 4.
Prior to launch of Tecentriq in each Member State the Marketing Authorisation Holder (MAH) must agree about the content and format of the educational programme, including communication media, 
Pred prihodom zdravila Tecentriq na trg v vsaki državi članici se mora imetnik dovoljenja za promet z zdravilom s pristojnim nacionalnim organom dogovoriti glede vsebine in oblike izobraževalnega programa, vključno s sredstvi obveščanja, načini razdeljevanja in vsemi ostalimi vidiki programa.
No dose reduction of atezolizumab was allowed. 
Zmanjšanje odmerka atezolizumaba ni bilo dovoljeno.
• Evidence of clinical benefit as assessed by the investigator 
• dokazi o klinični koristi po oceni raziskovalca.
51% of patients' tumours had PD-L1 expression of ≥ 1% TC or ≥ 1% IC and 49% of patients' tumours had PD-L1 expression of < 1% TC and < 1% IC. 
51 % tumorjev bolnikov je izražalo PD-L1 na ≥ 1 % TC ali ≥ 1% IC in 49 % tumorjev bolnikov je izražalo PD-L1 na < 1 % TC in < 1 % IC.
NE (11.1, NE) 
NO (11,1; NO)